Quick Answer
Kyverna Therapeutics, Inc. reported Cash and Equivalents of $124.09 million for fiscal year 2025.
Kyverna Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $124.09M | +28.4% |
| 2024 | $96.62M | +178.9% |
| 2023 | $34.65M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $34.16M | -67.4% | -36.1% |
| June 30, 2025 | $53.44M | -59.4% | -6.0% |
| March 31, 2025 | $56.87M | -74.6% | -41.1% |
| December 31, 2024 | $96.62M | +178.9% | -7.7% |
| September 30, 2024 | $104.66M | +355.7% | -20.5% |
| June 30, 2024 | $131.62M | +146.3% | -41.3% |
| March 31, 2024 | $224.29M | +463.7% | +547.3% |
| December 31, 2023 | $34.65M | — | +50.9% |
- Kyverna Therapeutics, Inc. showed an increase of +28.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Kyverna Therapeutics, Inc.’s cash and equivalents has grown by 258.2% (from $34.65 million to $124.09 million).
- The most recent figure is from Kyverna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: